AgingResearch.NewsJoin free

MDL-811

Intervention

1 paper2 findings

PubChem 169450636

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • Humans1

Outcomes

2

Mortality

downin mice1

1 study

  1. MDL-811 decreases mortality in mice.

    “administration of MDL-811 (20 mg/kg, i.p., every other day for 28 d) effectively mitigated AAD progression and reduced mortality”

    Animalsin BAPN-induced TAAD mice20 mg/kgevery other day for 28 d

    Sirtuin 6 mitigates thoracic aortic aneurysm progression via maintenance of mitochondria homeostasis in vascular smooth muscle cells

    Acta pharmacologica Sinica2 Sep 2025

Mitochondrial dysfunction

downin human cells1

1 study

  1. MDL-811 decreases mitochondrial dysfunction in human cells.

    “MDL-811, a newly developed small-molecule SIRT6 agonist, effectively reversed Ang II-induced mitochondrial dysfunction in HASMCs”

    Cellsin Ang II-treated HASMCs

    Sirtuin 6 mitigates thoracic aortic aneurysm progression via maintenance of mitochondria homeostasis in vascular smooth muscle cells

    Acta pharmacologica Sinica2 Sep 2025

Latest

Related